Steven Cohen Iovance Biotherapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$42.2 Billion
Q4 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 200,000 shares of IOVA stock, worth $696,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200,000

Holding current value

$696,000

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$4.44 - $8.79 $28.3 Million - $56 Million	-6,374,435 Reduced 81.86%	1,412,550 $6.43 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $5.43 Million - $9.18 Million	-1,013,074 Reduced 11.51%	7,786,985 $54.8 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $48.7 Million - $72.3 Million	8,800,059 New	8,800,059 $53.8 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $12.5 Million - $22.3 Million	-444,342 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $27.1 Million - $35.5 Million	-978,173 Reduced 68.76%	444,342 $14.6 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $44.7 Million - $67.4 Million	-1,642,711 Reduced 53.59%	1,422,515 $39 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $5.08 Million - $10.1 Million	259,996 Added 9.27%	3,065,226 $91.8 Million
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $36.3 Million - $59.5 Million	2,022,027 Added 258.17%	2,805,230 $77.6 Million
Q3 2019 Nov 15, 2019	BUY	$17.99 - $26.0 $6.11 Million - $8.83 Million	339,493 Added 76.51%	783,203 $14.3 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $4.34 Million - $10.9 Million	443,710 New	443,710 $10.9 Million

Others Institutions Holding IOVA

# of Institutions

342

Shares Held

247M

Call Options Held

2.51M

Put Options Held

3.5M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $549M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account